top of page

Class Cmm Drugs in Italy: Purchase and Prescription Behaviour in Hospitals

Writer's picture: Ulrich Neumann, MBA MSc MAUlrich Neumann, MBA MSc MA
Value in Health, Vol. 21, Suppl. 3 S. 165, October, 2018 · Jan 1, 2018
 

The 2012 Law Decree (D.L. n. 158/12 “Decreto Balduzzi”), introduced new regulation regarding authorization and classification of EMA authorised drugs, awaiting AIFA price and reimbursement (P&R) assessment. Under this Decree, drugs are temporarily classified as “class C non-negotiated” (Cnn) with the treatment cost being borne directly by patients (retail prescription market) or by hospitals. Scope of Cnn class introduction was to accelerate availability of novel treatments, just after EMA approval. Pending AIFA evaluation and finalisation of the P&R scheme (class H, A, A-PHT, C), manufacturers can decide whether to market it or not. This circumstance left hospitals and part of the industry with some uncertainty on the practicability of Cnn-drugs acquisition. Scope of our research was to understand and map hospital purchasing attitudes towards Cnn-drugs across all 20 Italian regions.





Kommentare


Vocal.

Sign up today and receive
fresh perspectives in your inbox.
Questions or suggestions?
Send a direct message below.

Success! Message received.

  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon
  • White Google+ Icon
bottom of page